相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Nita A. Limdi et al.
BLOOD (2010)
Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients
E. Pautas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
L. H. Cavallari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Roles for Vitamin K Beyond Coagulation
Sarah L. Booth
ANNUAL REVIEW OF NUTRITION (2009)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Virginia Perez-Andreu et al.
BLOOD (2009)
A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity
Myong-Jin Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Validation of Clinical Testing for Warfarin Sensitivity Comparison of CYP2C9-VKORC1 Genotyping Assays and Warfarin-Dosing Algorithms
Michael R. Langley et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
Matthew G. McDonald et al.
MOLECULAR PHARMACOLOGY (2009)
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
Jieying Eunice Zhang et al.
PHARMACOGENETICS AND GENOMICS (2009)
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
P. Borgiani et al.
PHARMACOGENOMICS (2009)
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
Stuart A. Scott et al.
PHARMACOGENOMICS (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients
J. A. Perini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics
Hedi Schelleman et al.
PHARMACOGENOMICS (2008)
Medication use leading to emergency department visits for adverse drug events in older adults
Daniel S. Budnitz et al.
ANNALS OF INTERNAL MEDICINE (2007)
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients
Liyan Miao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Bleeding complications with warfarin use - A prevalent adverse effect resulting in regulatory action
Diane K. Wysowski et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
VKORC1:: molecular target of coumarins
J. Oldenburg et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - Rationale and perspectives
Tong Yin et al.
THROMBOSIS RESEARCH (2007)
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose:: a prospective study
John F. Carlquist et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2006)
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
CL Aquilante et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
Harumi Takahashi et al.
PHARMACOGENETICS AND GENOMICS (2006)
Genomic regions exhibiting positive selection identified from dense genotype data
CS Carlson et al.
GENOME RESEARCH (2005)
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen
EA Sconce et al.
BLOOD (2005)
The influence of ethnicity on warfarin dosage requirement
MTN Dang et al.
ANNALS OF PHARMACOTHERAPY (2005)
Equal proportion of adult male and female homozygous for the 677C→T mutation in the methylenetetrahydrofolate reductase polymorphism
CAM Anderson et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2005)
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
M Wadelius et al.
PHARMACOGENOMICS JOURNAL (2005)
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea et al.
BLOOD (2005)
Genome scans of DNA variability in humans reveal evidence for selective sweeps outside of Africa
JF Storz et al.
MOLECULAR BIOLOGY AND EVOLUTION (2004)
The pharmacology and management of the vitamin K antagonists
J Ansell et al.
CHEST (2004)
The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis
KL Berkner et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Differences in drug pharmacokinetics between east Asians and Caucasians and the role of genetic polymorphisms
K Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
分享论文
